Mepo for Eosinophilic Esophagitis (EoE) Study
Condition: EoE; Eosinophilic Esophagitis
MeSH terms: Esophagitis; Eosinophilic Esophagitis
Intervention: Mepolizumab 300 mg; Mepolizumab 100 mg; Placebo
Intervention description: Mepolizumab 300 mg subcutaneous injection; Mepolizumab 100 mg subcutaneous injection; Saline subcutaneous injection
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 66.0
Sex: All
Minimum age: 16 Years
Maximum age: 75 Years
Healthy volunteers: No

Summary:

      Multi-center, randomized, double blind, parallel-arm, placebo controlled trial to determine
      whether mepolizumab is more effective than placebo for improving symptoms of dysphagia and
      decreasing esophageal eosinophil counts in adults and adolescents with active eosinophilic
      esophagitis (EoE) after an initial 3 month treatment course, and will also assess the impact
      of an additional 3 months of treatment.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age 16-75

          -  Diagnosis of EoE (eosinophilic esophagitis) as per consensus guidelines (including PPI
             non-response)*

          -  Active eosinophilia on esophageal biopsy, with a peak count of least 15 EOS/hpf
             (eosinophils per high power field) from at least one esophageal level.

          -  Biopsies from the stomach and duodenum that have ruled out alternative etiologies in
             all children and in adults with abnormal endoscopic findings or when other gastric or
             small intestinal conditions are clinical possibilities. If these samples have been
             obtained during a previous endoscopic evaluation and in the judgement of the
             site-Investigator the patient has not had a clinically significant change that would
             merit repeat gastric/duodenal biopsies, then prior normal gastric and duodenal
             biopsies are acceptable to exclude alternate etiologies.

          -  Active symptoms of dysphagia with more than 3 episodes of dysphagia over a period of 2
             weeks during the screening period, and an Eosinophilic Esophagitis Symptom Activity
             Index (EEsAI; see below for details) score of ≥ 27 at baseline.

          -  Able to read, comprehend, and sign consent form.

          -  Have maintained a stable diet for 6 weeks prior to enrollment.

          -  Able to maintain a stable diet throughout the duration of the study period.

          -  Female subjects of childbearing potential who have had their first menses agree to use
             a highly effective method of birth control during the study and for 30 days after the
             last dose of study drug. Female subjects with reproductive potential who are using
             systemic contraceptives (e.g., oral contraceptives, injectable contraceptives,
             implantable/insertable hormonal contraceptive products, or transdermal patches) to
             prevent pregnancy must have stable use for ≥28 days prior to screening.

               -  PPI non-response is defined as >15 eos/hpf after at least 6 weeks of high dose
                  administration (40mg total per day or higher) of any approved PPI medication or
                  documented evidence of intolerance or allergy to PPIs. The length of the PPI
                  trial period or documented intolerance/allergy will be determined according to
                  the local clinical standard of care.

        Exclusion Criteria:

          -  Esophageal dilation within 8 weeks of the screening endoscopy.

          -  Inability to pass a standard upper endoscope (8-10mm) due to esophageal narrowing or
             stricturing.

          -  Swallowed/topical steroids for EoE within 4 weeks of the screening endoscopy, or a
             course of systemic corticosteroids within 8 weeks of the screening endoscopy.

          -  Not having maintained a stable diet for at least 6 weeks preceding the screening
             endoscopy.

          -  Initiation, discontinuation, or change of dose regimen of PPIs; leukotriene
             inhibitors; or nasal, inhaled, and/or orally administered topical corticosteroids for
             any condition (such as gastroesophageal reflux disease, asthma, or allergic rhinitis)
             within the 8 weeks prior to the qualifying esophagogastroduodenoscopy (EGD).

          -  Presence of concomitant eosinophilic gastritis (EG), eosinophilic gastroenteritis
             (EGE), eosinophilic colitis (EC), Crohn's disease, ulcerative colitis, or celiac
             disease.

          -  History of malignancy within 5 years prior to screening, except completely treated in
             situ carcinoma of the cervix and completely treated non-metastatic squamous or basal
             cell carcinoma of the skin.

          -  History of achalasia.

          -  Prior esophageal surgery.

          -  History of bleeding disorder or esophageal varices.

          -  Active parasitic infection or suspicion of an active parasitic infection, which, in
             the opinion of the site-Investigator, has not been previously evaluated or treated.
             Subjects presenting with signs of active parasitic infection or suspicion of active
             parasitic infection as assessed by current diarrhea and/or blood or mucus in stool
             will be referred to their clinical physician for further testing to rule out parasitic
             infection.

          -  Any other active infections judged at the discretion of the site-Investigator.

          -  Any other medical or psychological condition that, in the opinion of the
             site-investigator, may present an unreasonable risk to the study patient as a result
             of his/her participation in this clinical trial, may make patient's participation
             unreliable, or may interfere with study assessments. The specific justification for
             patients excluded under this criterion will be noted in study documents.

          -  Patient or his/her immediate family is a member of the investigational team.

          -  Pregnancy or breastfeeding.

          -  Women of children bearing potential who are not on highly-effective contraception.